MultiCare Health System

Main Phone Number800-342-9919   Online ChatOnline Chat
Institute for Research & Innovation

Multiple Sclerosis - Relapse (Ages 18-55)

Title: A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sclerosis

Purpose: This study is seeking patients who have clinically diagnosed Multiple Sclerosis with at least 2 documented clinical attacks (relapses) within the last 2 years. This study is comparing Ocrelizumab to Rebif.

Who Can Participate?
Patients who meet the relapse criteria listed above. Medication restrictions may apply depending of what type of MS modifying therapy you are currently using.

Diagnosis or Condition
: Patients with a clinical diagnosis of Multiple Sclerosis

Medication
: Investigational Product is delivered via IV infusion every 6 months.  

Age
: Between 18 and 55 years of age

Sex
: Males and Females

Visits
:   Patients will be followed for up to 96 weeks and includes 4 infusion treatment cycles every 6 months

Stipend
: You will be compensated for your time and travel

Principal Investigator(s)John Huddlestone, MD, FAAN

Study Coordinator
:   Andrea Thompson, 253-403-7440